Sano K, Kataoka S, Katoh T, Kawauchi H, Morikawa S
Department of Otolaryngology, Shimane Medical University, Izumo.
Nihon Jibiinkoka Gakkai Kaiho. 1997 Jul;100(7):790-7. doi: 10.3950/jibiinkoka.100.790.
It has been demonstrated that CYFRA 21-1 (ELISA kit), which recognizes the soluble cytokeratin 19 fragment, is useful for assessing circulating tumor antigens in sera of patients with lung cancer. In this study, we compared the clinical significance of this new marker with the established squamous cell carcinoma antigen (SCC Ag), using sera from patients with head and neck malignant disease, healthy controls, and supernatants of established cell lines derived from squamous cell carcinomas and adenocarcinomas. The subjects were: Group A, 39 patients with malignant disease of the head and neck. Group B, 11 patients considered to be tumor-free after treatment. Group C, 67 patients with benign disease or healthy volunteers. Culture supernatants: 11 cell lines established from squamous cell carcinomas and adenocarcinomas. Serum levels of CYFRA 21-1 and SCC Ag of group A were significantly higher than those of group C. This finding suggests that CYFRA 21-1 is useful as a tumor marker as well as SCC Ag. CYFRA 21-1 and SCC Ag levels of patients in group A at the early and progressive stages of disease were comparable to the levels in group C. Both tumor markers are therefore useful for diagnosis of in the early stage of cancer. We attempted to set a cut-off level of CYFRA 21-1. The sensitivity of CYFRA 21-1 is higher than that of SCC Ag, especially in patients in the early stage of the disease. This finding indicates that the CYFRA 21-1 is preferable to SCC Ag as a tumor marker for the diagnosis of patients even in the early stages of malignant disease. The levels of CYFRA 21-1 in culture supernatants derived from tumor cell lines are higher than those of SCC Ag in all cell lines. The levels of CYFRA 21-1 are measurable, with levels varying with the cell line. There appears to be no correlation between the level of CYFRA 21-1 and the character of the cell lines, but this issue remains to be further investigated.
已证实，可识别可溶性细胞角蛋白19片段的CYFRA 21-1（酶联免疫吸附测定试剂盒），对于评估肺癌患者血清中的循环肿瘤抗原很有用。在本研究中，我们使用头颈部恶性疾病患者的血清、健康对照以及源自鳞状细胞癌和腺癌的已建立细胞系的上清液，比较了这一新标志物与已确立的鳞状细胞癌抗原（SCC Ag）的临床意义。研究对象包括：A组，39名头颈部恶性疾病患者；B组，11名经治疗后被认为无肿瘤的患者；C组，67名患有良性疾病的患者或健康志愿者。培养上清液：11种源自鳞状细胞癌和腺癌的已建立细胞系。A组的CYFRA 21-1和SCC Ag血清水平显著高于C组。这一发现表明CYFRA 21-1与SCC Ag一样，可作为一种肿瘤标志物。A组处于疾病早期和进展期患者的CYFRA 21-1和SCC Ag水平与C组相当。因此，这两种肿瘤标志物都有助于癌症早期诊断。我们试图设定CYFRA 21-1的临界值。CYFRA 21-1的敏感性高于SCC Ag，尤其是在疾病早期的患者中。这一发现表明，即使对于恶性疾病早期的患者，CYFRA 21-1作为肿瘤标志物也优于SCC Ag。源自肿瘤细胞系的培养上清液中CYFRA 21-1的水平在所有细胞系中均高于SCC Ag。CYFRA 21-1的水平是可测量的，且水平随细胞系而异。CYFRA 21-1的水平与细胞系的特征之间似乎没有相关性，但这一问题仍有待进一步研究。
